Pregnant women with hepatitis b: new study tests safer drug to shield babies

NCT ID NCT07542951

First seen May 01, 2026 ยท Last updated May 01, 2026

Summary

This study looks at two antiviral medications, TAF and TDF, in pregnant women with chronic hepatitis B. The goal is to see which drug is better at preventing the virus from passing to the baby and to check for any side effects. About 200 pregnant women will take one of the drugs daily from early or middle pregnancy until delivery, with regular checkups. The results will help doctors choose the safest and most effective treatment for both mother and child.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B VIRUS INFECTION; PREGNANT WOMEN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Department of Infectious Diseases, Guangdong Provincial Key Laboratory of Major Obstetric Diseases; Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital, Guangzhou Medical University,

    Guangzhou, Guangdong, 450000, China

Conditions

Explore the condition pages connected to this study.